-
Review concluded regarding general reimbursement for Valsartan/Hydrochlorothiazide "Actavis"
| 08 March 2012 |
We have completed our review of an application for general reimbursement for Valsartan/Hydrochlorothiazide "Actavis". The product is neither eligible for general nor general conditional reimbursement.
-
Comments received on the reassessment of reimbursement status of antidiabetic medicines (ATC group A10)
| 06 March 2012 |
The Danish National Board of Health has received a number of comments from stakeholders about the Reimbursement Committee's discussion of the reimbursement status of antidiabetic medicines (ATC group A10).
All items (457)
-
Time
- 2024 (18)
- 2023 (24)
- 2022 (20)
- 2021 (44)
- 2020 (62)
- 2019 (20)
- 2018 (37)
- 2017 (54)
- 2016 (53)
- 2015 (11)
- 2014 (13)
- 2013 (11)
- 2012 (11)
- 2011 (13)
- 2010 (9)
- 2009 (14)
- 2008 (7)
- 2007 (3)
- 2006 (10)
- 2014 (13)
- 2015 (11)
- 2016 (53)
- 2017 (54)
- 2018 (37)
- 2019 (20)
- 2020 (62)
- 2021 (44)
- 2022 (20)
- 2023 (24)
- 2006 (10)
- 2009 (14)
- 2010 (9)
- 2013 (11)
- 2024 (18)
- 2007 (3)
- 2011 (13)
- 2012 (11)
- 2008 (7)
- 2020 (62)
- 2021 (44)
- 2022 (20)
- 2023 (24)
- 2024 (18)
- 2010 (9)
- 2011 (13)
- 2012 (11)
- 2015 (11)
- 2016 (53)
- 2017 (54)
- 2018 (37)
- 2019 (20)